+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia



Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia



Current Medical Research and Opinion 30(2): 223-228



To investigate the distribution of statin therapy correlated gene polymorphism allele CYP2D6*10 (C188T) in Ningxia Hui nationality and to discuss the relationship between the gene polymorphism allele CYP2D6*10 (C188T) and the lipid-lowering efficacy of simvastatin and hyperlipidemia. One hundred and fifty healthy people (80 males and 70 females) and 200 hyperlipidemia patients (105 males and 95 females) were recruited at Ningxia People's Hospital. Genotypes were determined by using allele-specific amplification (ASA-PCR) in 150 healthy controls and 200 patients with hyperlipidemia. Relationships between genotypes and lipid levels and the lipid-lowering efficacy of simvastatin were analyzed. The distribution frequency of the CYP2D6*10 allele was 47.6% in the Ningxia Hui nationality. There was no significant correlation between the CYP2D6*10 allele and hyperlipidemia. At 8 weeks after treatment with simvastatin, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were more obviously decreased with the CC genotype than the CT and TT genotypes, with significant differences. Distribution of the gene polymorphism of CYP2D6*10 is ethnically and geographical different. The allele T of CYP2D6*10 is not related to hyperlipidemia. CC expression seemed to increase the lipid-lowering effects of simvastatin. The hyperlipidemia patients with CC genotype should take lower doses of simvastatin than those with CT/TT genotype in the Ningxia Hui population.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911215

Download citation: RISBibTeXText

PMID: 24156754

DOI: 10.1185/03007995.2013.858619


Related references

CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenetics and Genomics 17(9): 695-707, 2007

Association of CYP2D6 gene polymorphism and psychoactive drug therapy side effects. Clinical Chemistry & Laboratory Medicine 39(Special Supplement): S50, 2001

CYP2D6 polymorphism in a Gabonese population: Contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. British Journal of Clinical Pharmacology 47(1): 121-124, 1999

Polymorphism of CYP3A4 2 and eNOS genes in the diabetic patients with hyperlipidemia undergoing statin treatment. Molecular Biology Reports 41(10): 6719-6727, 2015

1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study. Drug Metabolism and Personalized Therapy 31(4): 205-212, 2016

Statin therapy for hyperlipidemia. JAMA 310(11): 1185-1185, 2013

Cholesteryl ester transfer protein rs1532624 gene polymorphism is associated with reduced response to statin therapy. Current Molecular Pharmacology 6(3): 156-162, 2015

Alternate-day statin therapy for the treatment of hyperlipidemia. Annals of PharmacoTherapy 44(9): 1459-1470, 2010

Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy. Giornale Italiano di Cardiologia 12(3): 182-185, 2011

Statin-fibrate combination: therapy for hyperlipidemia: a review. Current Medical Research and Opinion 19(3): 155-168, 2003

Debrisoquine polymorphism: Novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbe Guaymi Indian of Panama. Pharmacogenetics 1(3): 136-142, 1991

Is combined statin and fibrate therapy indicated in the management of mixed hyperlipidemia?. Presse Medicale 27(15): 720-722, 1998